Functional and structural reverse myocardial remodeling following transcatheter aortic valve replacement: a prospective cardiovascular magnetic resonance study.
Aortic Valve
/ diagnostic imaging
Aortic Valve Stenosis
/ diagnostic imaging
Contrast Media
Gadolinium
Heart Failure
Humans
Magnetic Resonance Spectroscopy
Predictive Value of Tests
Prospective Studies
Stroke Volume
Transcatheter Aortic Valve Replacement
/ adverse effects
Treatment Outcome
Ventricular Function, Left
Ventricular Remodeling
Assessment of myocardial function and structure
Cardiac magnetic resonance imaging
Myocardial remodeling
Transcatheter aortic valve replacement
Journal
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
ISSN: 1532-429X
Titre abrégé: J Cardiovasc Magn Reson
Pays: England
ID NLM: 9815616
Informations de publication
Date de publication:
28 07 2022
28 07 2022
Historique:
received:
03
01
2022
accepted:
29
06
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
30
7
2022
Statut:
epublish
Résumé
Since cardiovascular magnetic resonance (CMR) imaging allows comprehensive quantification of both myocardial function and structure we aimed to assess myocardial remodeling processes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR). CMR imaging was performed in 40 patients with severe AS before and 1 year after TAVR. Image analyses comprised assessments of myocardial volumes, CMR-feature-tracking based atrial and ventricular strain, myocardial T1 mapping, extracellular volume fraction-based calculation of left ventricular (LV) cellular and matrix volumes, as well as ischemic and non-ischemic late gadolinium enhancement analyses. Moreover, biomarkers including NT-proBNP as well as functional and clinical status were documented. Myocardial function improved 1 year after TAVR: LV ejection fraction (57.9 ± 16.9% to 65.4 ± 14.5%, p = 0.002); LV global longitudinal (- 21.4 ± 8.0% to -25.0 ± 6.4%, p < 0.001) and circumferential strain (- 36.9 ± 14.3% to - 42.6 ± 11.8%, p = 0.001); left atrial reservoir (13.3 ± 6.3% to 17.8 ± 6.7%, p = 0.001), conduit (5.5 ± 3.2% to 8.4 ± 4.6%, p = 0.001) and boosterpump strain (8.2 ± 4.6% to 9.9 ± 4.2%, p = 0.027). This was paralleled by regression of total myocardial volume (90.3 ± 21.0 ml/m CMR imaging enables comprehensive detection of myocardial remodeling in patients undergoing TAVR. Regression of LV matrix volume as a surrogate for reversible diffuse myocardial fibrosis is accompanied by increase of myocardial function and recovery from heart failure. Further data are required to define the value of these parameters as therapeutic targets for optimized management of TAVR patients. Trial registration DRKS, DRKS00024479. Registered 10 December 2021-Retrospectively registered, https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024479.
Sections du résumé
BACKGROUND
Since cardiovascular magnetic resonance (CMR) imaging allows comprehensive quantification of both myocardial function and structure we aimed to assess myocardial remodeling processes in patients with severe aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR).
METHODS
CMR imaging was performed in 40 patients with severe AS before and 1 year after TAVR. Image analyses comprised assessments of myocardial volumes, CMR-feature-tracking based atrial and ventricular strain, myocardial T1 mapping, extracellular volume fraction-based calculation of left ventricular (LV) cellular and matrix volumes, as well as ischemic and non-ischemic late gadolinium enhancement analyses. Moreover, biomarkers including NT-proBNP as well as functional and clinical status were documented.
RESULTS
Myocardial function improved 1 year after TAVR: LV ejection fraction (57.9 ± 16.9% to 65.4 ± 14.5%, p = 0.002); LV global longitudinal (- 21.4 ± 8.0% to -25.0 ± 6.4%, p < 0.001) and circumferential strain (- 36.9 ± 14.3% to - 42.6 ± 11.8%, p = 0.001); left atrial reservoir (13.3 ± 6.3% to 17.8 ± 6.7%, p = 0.001), conduit (5.5 ± 3.2% to 8.4 ± 4.6%, p = 0.001) and boosterpump strain (8.2 ± 4.6% to 9.9 ± 4.2%, p = 0.027). This was paralleled by regression of total myocardial volume (90.3 ± 21.0 ml/m
CONCLUSION
CMR imaging enables comprehensive detection of myocardial remodeling in patients undergoing TAVR. Regression of LV matrix volume as a surrogate for reversible diffuse myocardial fibrosis is accompanied by increase of myocardial function and recovery from heart failure. Further data are required to define the value of these parameters as therapeutic targets for optimized management of TAVR patients. Trial registration DRKS, DRKS00024479. Registered 10 December 2021-Retrospectively registered, https://www.drks.de/drks_web/navigate.do?navigationId=trial.HTML&TRIAL_ID=DRKS00024479.
Identifiants
pubmed: 35897100
doi: 10.1186/s12968-022-00874-0
pii: 10.1186/s12968-022-00874-0
pmc: PMC9331125
doi:
Substances chimiques
Contrast Media
0
Gadolinium
AU0V1LM3JT
Banques de données
DRKS
['DRKS00024479']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
45Subventions
Organisme : German Research Foundation
ID : DFG
Organisme : German Research Foundation
ID : CRC 1002
Organisme : German Research Foundation
ID : D1
Informations de copyright
© 2022. The Author(s).
Références
J Am Heart Assoc. 2017 Jul 11;6(7):
pubmed: 28698259
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
JACC Cardiovasc Imaging. 2018 Oct;11(10):1433-1444
pubmed: 29454776
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
JACC Cardiovasc Imaging. 2022 May;15(5):943-945
pubmed: 35512961
JACC Cardiovasc Interv. 2018 Mar 26;11(6):593-601
pubmed: 29501544
J Cardiovasc Magn Reson. 2020 Jun 22;22(1):46
pubmed: 32564773
J Am Coll Cardiol. 2013 Sep 10;62(11):1002-12
pubmed: 23727214
J Am Coll Cardiol. 2011 Sep 13;58(12):1271-9
pubmed: 21903062
Int J Cardiovasc Imaging. 2018 Jan;34(1):97-112
pubmed: 28642994
J Cardiovasc Magn Reson. 2020 Jun 1;22(1):41
pubmed: 32475350
Circulation. 1984 May;69(5):855-65
pubmed: 6231136
N Engl J Med. 2010 Oct 21;363(17):1597-607
pubmed: 20961243
N Engl J Med. 2016 Apr 28;374(17):1609-20
pubmed: 27040324
Circulation. 2021 Apr 13;143(15):1484-1498
pubmed: 33472397
PLoS One. 2018 Mar 14;13(3):e0193746
pubmed: 29538467
N Engl J Med. 2014 May 8;370(19):1790-8
pubmed: 24678937
J Cardiovasc Magn Reson. 2013 Oct 14;15:92
pubmed: 24124732
J Am Coll Cardiol. 2018 Apr 17;71(15):1696-1706
pubmed: 29650126
J Cardiovasc Magn Reson. 2012 Dec 28;14:88
pubmed: 23272651
J Hypertens. 2017 Apr;35(4):853-861
pubmed: 28253222
Eur Heart J. 2017 Sep 21;38(36):2739-2791
pubmed: 28886619
Eur Radiol. 2020 Jan;30(1):640-651
pubmed: 31407030
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):307-15
pubmed: 25246506
Can J Cardiol. 2016 Dec;32(12):1411-1418
pubmed: 27523272
Circulation. 1989 Apr;79(4):744-55
pubmed: 2522356
JACC Cardiovasc Imaging. 2017 Nov;10(11):1320-1333
pubmed: 28017384
Eur Heart J. 2018 Feb 21;39(8):699-709
pubmed: 29020257
JACC Cardiovasc Imaging. 2020 Nov;13(11):2343-2354
pubmed: 32563637
Magn Reson Med. 2021 Jan;85(1):357-368
pubmed: 32851707
Circ Cardiovasc Imaging. 2016 Apr;9(4):e004077
pubmed: 27009468
Radiology. 2020 Aug;296(2):299-309
pubmed: 32544032
J Am Coll Cardiol. 2020 Jan 28;75(3):304-316
pubmed: 31976869
Cardiovasc Ultrasound. 2010 Jul 26;8:29
pubmed: 20659321
Eur Heart J. 2020 May 21;41(20):1903-1914
pubmed: 32049275
JACC Cardiovasc Imaging. 2019 Feb;12(2):283-296
pubmed: 30732723
J Am Coll Cardiol. 2018 Feb 27;71(8):860-871
pubmed: 29471937
Eur Heart J. 2022 Feb 12;43(7):561-632
pubmed: 34453165
J Am Coll Cardiol. 2016 Jan 26;67(3):251-60
pubmed: 26796388
Eur Heart J. 2018 Jul 21;39(28):2635-2642
pubmed: 29546396
Lancet. 2006 Sep 16;368(9540):1005-11
pubmed: 16980116
Eur Heart J. 2017 Dec 01;38(45):3351-3358
pubmed: 29020232
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811